3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00)

A.Roth; S.Tejpar; P.Yan; R.Fiocca; S.Hsu Schmitz; G.Bodoky; R.Labianca; D.Cunningham; E.van Cutsem; F.Bosman

首页> 外文期刊>European Journal of Cancer Supplements >3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00)

【24h】

3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00)

机译：3013结肠癌（COC）中的ORAL组织生物标志物：III期临床试验的转化研究早期结果，该试验比较了II期阶段中注入的伊立替康/ 5-氟尿嘧啶（5-FU）/亚叶酸（FA）与5-FU / FA的比较III级COC患者（PETACC 3–EORTC 40993–SAKK 60/00）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
A.Roth; S.Tejpar; P.Yan; R.Fiocca; S.Hsu Schmitz; G.Bodoky; R.Labianca; D.Cunningham; E.van Cutsem; F.Bosman;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. [J] . Roth AD, Tejpar S, Delorenzi Journal of Clinical Oncology . 2010,第3期

机译：KRAS和BRAF在第二和第三阶段切除的结肠癌中的预后作用：PETACC-3，EORTC 40993，SAKK 60-00试验的翻译研究结果。
2. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study [J] . K?hneC.-H., BedenneL., CarratoA., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第8期

机译：一项III期随机对照试验，比较了大剂量输注5-氟尿嘧啶或不加亚叶酸与标准推注5-氟尿嘧啶/亚叶酸在III期结肠癌辅助治疗中的应用：泛欧辅助性结肠癌试验2
3. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. [J] . Glimelius B, Sorbye H, Balteskard L, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第5期

机译：一项随机III期多中心试验，比较了伊立替康与转移性结直肠癌患者的北欧快速推注5-FU和亚叶酸方案或推注/注入的格拉蒙特方案（Lv5FU2）。
4. NET-02 trial protocol: a multicentre randomised parallel group open-label phase II single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) [O] . Zoe Craig, Jayne Swain, Emma Batman, 2020

机译：NET-02试验方案：脂质体伊立替康（nal-IRI）和5-氟尿嘧啶（5-FU）/亚叶酸或多西他赛的多中心随机平行组开放标签II期单阶段选择试验进行性低分化肺外神经内分泌癌（NEC）患者的在线治疗
5. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [O] . Souglakos, J, Androulakis, N, Syrigos, K, 2006

机译：FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）与FOLFIRI（亚叶酸，5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）

3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00)

著录项

相似文献

相关主题

期刊订阅